Contract with Screen4

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Contract with Screen4 for COVID-19 antibody laboratory-based testing service

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has signed a contract with Screen4 Ltd ("Screen4") to provide a testing service using the Mologic ELISA1 antibody test for COVID-19 from the Company's in-house testing laboratory in Littleport, Cambridgeshire.

This follows the launch of the COVID-19 antibody testing service, as announced on 26 January 2021. The contract is for an initial term of three years.

Screen4 is a leading provider of COVID-19 testing services and diagnostic testing services to the aviation, petrochemical, occupational health and consumer markets in the UK and across the Middle east and Far East regions. Screen4 is an Approved Provider under the UK Government General testing and 'Test to Release' Scheme in the UK.

Colin King, CEO of Omega, commented: "Following on from setting up and launching our in-house testing service that utilises the Mologic COVID-19 IgG ELISA, I am pleased to be working with Screen4 as our first customer. Screen4 provide a synergistic approach involving health assessment and patient support to their clients."

David Grouse, Managing Director of Screen4, commented: "We are delighted to be involved with Omega Diagnostics on this project. Omega are at the forefront in the development of vital testing technologies to help fight the Covid-19 virus. We will be supporting them through the distribution of their latest product - the COVID-19 ELISA Antibody testing service. The simple, usable nature of this product, particularly with regards to a properly CE marked self-collection sample kit for Home Use, is a major step forward in helping people understand their current status with regards to the virus."

1 ELISA (Enzyme Linked Immuno-Sorbent Assay) tests are one of the most tested and proven laboratory technologies used by the global diagnostic industry and remain the principal reference point from which rapid diagnostics are coordinated, especially serological tests, including tests for COVID-19.

Contacts: